New antibody drug tested for stubborn digestive cancers
NCT ID NCT05639153
First seen Apr 16, 2026 · Last updated May 15, 2026 · Updated 4 times
Summary
This early-stage study tested a new drug called DR30303 in 13 people with advanced digestive system cancers that had stopped responding to standard treatments. The drug is a lab-made antibody designed to attach to a specific protein (CLDN18.2) on cancer cells. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASM OF DIGESTIVE SYSTEM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sir Run Run Shaw Hospital，Zhejiang University School of Medicine
Hanzhou, Zhejiang, 311100, China
Conditions
Explore the condition pages connected to this study.